Top

Clinical Reviews in Allergy & Immunology

Published in:

Open Access 01-04-2019

Mast Cell-Mediated Orchestration of the Immune Responses in Human Allergic Asthma: Current Insights

Authors: Daniel Elieh Ali Komi, Leif Bjermer

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2019

Abstract

Improving the lung function after experimental allergen challenge by blocking of mast cell (MC) mediators and the capability of MC mediators (including histamine, prostaglandin (PG) D2, and leukotriene (LT) C4) in induction of mucosal edema, bronchoconstriction, and mucus secretion provide evidence that MCs play a key role in pathophysiology of asthma. In asthma, the number of MCs increases in the airways and infiltration of MCs in a variety of anatomical sites including the epithelium, the submucosal glands, and the smooth muscle bundles occurs. MC localization within the ASM is accompanied with the hypertrophy and hyperplasia of the layer, and smooth muscle dysfunction that is mainly observed in forms of bronchial hyperresponsiveness, and variable airflow obstruction. Owing to the expression of a wide range of surface receptors and releasing various cytoplasmic mediators, MCs orchestrate the pathologic events of the disease. MC-released preformed mediators including chymase, tryptase, and histamine and de novo synthesized mediators such as PGD2, LTC4, and LTE4 in addition of cytokines mainly TGFβ1, TSLP, IL-33, IL-4, and IL-13 participate in pathogenesis of asthma. The release of MC mediators and MC/airway cell interactions during remodeling phase of asthma results in persistent cellular and structural changes in the airway wall mainly epithelial cell shedding, goblet cell hyperplasia, hypertrophy of ASM bundles, fibrosis in subepithelial region, abnormal deposition of extracellular matrix (ECM), increased tissue vascularity, and basement membrane thickening. We will review the current knowledge regarding the participation of MCs in each stage of asthma pathophysiology including the releasing mediators and their mechanism of action, expression of receptors by which they respond to stimuli, and finally the pharmaceutical products designed based on the strategy of blocking MC activation and mediator release.

Komi DE, Kazemi T, Bussink AP (2016) New insights into the relationship between chitinase-3-like-1 and asthma. Curr Allergy Asthma Rep 16(8):57. https://doi.org/10.1007/s11882-016-0637-2 CrossRefPubMed

Singh M, Das S, Chauhan A, Paul N, Sodhi KS, Mathew J, Chakrabarti A (2015) The diagnostic criteria for allergic bronchopulmonary aspergillosis in children with poorly controlled asthma need to be re-evaluated. Acta Paediatr 104(5):e206–e209. https://doi.org/10.1111/apa.12930 CrossRefPubMed

Akoto C, Davies DE, Swindle EJ (2017) Mast cells are permissive for rhinovirus replication: potential implications for asthma exacerbations. Clin Exp Allergy 47(3):351–360. https://doi.org/10.1111/cea.12879 CrossRefPubMedPubMedCentral

Wong TH, Lee CL, Su HH, Lee CL, Wu CC, Wang CC, Sheu CC, Lai RS, Leung SY, Lin CC, Wei YF, Wang CJ, Lin YC, Chen HL, Huang MS, Yen JH, Huang SK, Suen JL (2018) A prominent air pollutant, Indeno[1,2,3-cd]pyrene, enhances allergic lung inflammation via aryl hydrocarbon receptor. Sci Rep 8(1):5198. https://doi.org/10.1038/s41598-018-23542-9 CrossRefPubMedPubMedCentral

Boita M, Heffler E, Omede P, Bellocchia M, Bussolino C, Solidoro P, Giorgis V, Guerrera F, Riva G, Brussino L, Bucca C, Rolla G (2018) Basophil membrane expression of epithelial cytokine receptors in patients with severe asthma. Int Arch Allergy Immunol 175(3):171–176. https://doi.org/10.1159/000486314 CrossRefPubMed

Allakhverdi Z, Comeau MR, Jessup HK, Yoon BR, Brewer A, Chartier S, Paquette N, Ziegler SF, Sarfati M, Delespesse G (2007) Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 204(2):253–258. https://doi.org/10.1084/jem.20062211 CrossRefPubMedPubMedCentral

Andersson CK, Bergqvist A, Mori M, Mauad T, Bjermer L, Erjefalt JS (2011) Mast cell-associated alveolar inflammation in patients with atopic uncontrolled asthma. J Allergy Clin Immunol 127(4):905–912.e901-907. https://doi.org/10.1016/j.jaci.2011.01.022 CrossRefPubMed

Bergqvist A, Andersson CK, Mori M, Walls AF, Bjermer L, Erjefalt JS (2015) Alveolar T-helper type-2 immunity in atopic asthma is associated with poor clinical control. Clin Sci (Lond) 128(1):47–56. https://doi.org/10.1042/cs20140309 CrossRef

Andersson CK, Weitoft M, Rydell-Tormanen K, Bjermer L, Westergren-Thorsson G, Erjefalt JS (2018) Uncontrolled asthmatics have increased FceRI(+) and TGF-beta-positive MCTC mast cells and collagen VI in the alveolar parenchyma. Clin Exp Allergy 48(3):266–277. https://doi.org/10.1111/cea.13092 CrossRefPubMed

10.

Elieh-Ali-Komi D, Cao Y (2017) Role of mast cells in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Rev Allergy Immunol 52(3):436–445. https://doi.org/10.1007/s12016-016-8595-y CrossRefPubMed

11.

Elieh Ali Komi D, Rambasek T, Bielory L (2018) Clinical implications of mast cell involvement in allergic conjunctivitis. Allergy 73(3):528–539. https://doi.org/10.1111/all.13334 CrossRefPubMed

12.

Elieh Ali Komi D, Grauwet K (2017) Role of mast cells in regulation of T cell responses in experimental and clinical settings. Clin Rev Allergy Immunol 54:432–445. https://doi.org/10.1007/s12016-017-8646-z CrossRef

13.

Komi DEA, Rambasek T, Wohrl S (2017) Mastocytosis: from a molecular point of view. Clin Rev Allergy Immunol. https://doi.org/10.1007/s12016-017-8619-2

14.

Ali H (2016) Mas-related G protein coupled receptor-X2: a potential new target for modulating mast cell-mediated allergic and inflammatory diseases. J Immunobiol 1(4)

15.

Andersson C, Tufvesson E, Diamant Z, Bjermer L (2016) Revisiting the role of the mast cell in asthma. Curr Opin Pulm Med 22(1):10–17. https://doi.org/10.1097/mcp.0000000000000228 CrossRefPubMed

16.

Kubo M (2017) Innate and adaptive type 2 immunity in lung allergic inflammation. Immunol Rev 278(1):162–172. https://doi.org/10.1111/imr.12557 CrossRefPubMed

17.

Lambrecht BN, Hammad H (2015) The immunology of asthma. Nat Immunol 16(1):45–56. https://doi.org/10.1038/ni.3049 CrossRef

18.

Zhu J (2015) T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine 75(1):14–24. https://doi.org/10.1016/j.cyto.2015.05.010 CrossRefPubMedPubMedCentral

19.

Motomura Y, Morita H, Moro K, Nakae S, Artis D, Endo TA, Kuroki Y, Ohara O, Koyasu S, Kubo M (2014) Basophil-derived interleukin-4 controls the function of natural helper cells, a member of ILC2s, in lung inflammation. Immunity 40(5):758–771. https://doi.org/10.1016/j.immuni.2014.04.013 CrossRefPubMed

20.

Xue L, Salimi M, Panse I, Mjosberg JM, McKenzie AN, Spits H, Klenerman P, Ogg G (2014) Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol 133(4):1184–1194. https://doi.org/10.1016/j.jaci.2013.10.056 CrossRefPubMedPubMedCentral

21.

Saatian B, Rezaee F, Desando S, Emo J, Chapman T, Knowlden S, Georas SN (2013) Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway epithelial cells. Tissue Barriers 1(2):e24333. https://doi.org/10.4161/tisb.24333 CrossRefPubMedPubMedCentral

22.

Saluja R, Khan M, Church MK, Maurer M (2015) The role of IL-33 and mast cells in allergy and inflammation. Clin Transl Allergy 5:33. https://doi.org/10.1186/s13601-015-0076-5 CrossRefPubMedPubMedCentral

23.

Lambrecht BN, Hammad H (2013) Asthma: the importance of dysregulated barrier immunity. Eur J Immunol 43(12):3125–3137. https://doi.org/10.1002/eji.201343730 CrossRefPubMed

24.

Lambrecht BN, Persson EK, Hammad H (2017) Myeloid cells in asthma. Microbiol Spectr 5(1). https://doi.org/10.1128/microbiolspec.MCHD-0053-2016

25.

Wilson SJ, Rigden HM, Ward JA, Laviolette M, Jarjour NN, Djukanovic R (2013) The relationship between eosinophilia and airway remodelling in mild asthma. Clin Exp Allergy 43(12):1342–1350. https://doi.org/10.1111/cea.12156 CrossRefPubMedPubMedCentral

26.

Metcalfe DD, Pawankar R, Ackerman SJ, Akin C, Clayton F, Falcone FH, Gleich GJ, Irani AM, Johansson MW, Klion AD, Leiferman KM, Levi-Schaffer F, Nilsson G, Okayama Y, Prussin C, Schroeder JT, Schwartz LB, Simon HU, Walls AF, Triggiani M (2016) Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ J 9(7):7. https://doi.org/10.1186/s40413-016-0094-3 CrossRefPubMedPubMedCentral

27.

Sulaiman I, Lim JC, Soo HL, Stanslas J (2016) Molecularly targeted therapies for asthma: current development, challenges and potential clinical translation. Pulm Pharmacol Ther 40:52–68. https://doi.org/10.1016/j.pupt.2016.07.005 CrossRefPubMed

28.

Yu QN, Guo YB, Li X, Li CL, Tan WP, Fan XL, Qin ZL, Chen D, Wen WP, Zheng SG, Fu QL (2018) ILC2 frequency and activity are inhibited by glucocorticoid treatment via STAT pathway in patients with asthma. Allergy 73:1860–1870. https://doi.org/10.1111/all.13438 CrossRefPubMedPubMedCentral

29.

Elieh Ali Komi D, Sharma L, Dela Cruz CS (2018) Chitin and its effects on inflammatory and immune responses. Clin Rev Allergy Immunol 54(2):213–223. https://doi.org/10.1007/s12016-017-8600-0 CrossRefPubMed

30.

Kaur D, Hollins F, Woodman L, Yang W, Monk P, May R, Bradding P, Brightling CE (2006) Mast cells express IL-13R alpha 1: IL-13 promotes human lung mast cell proliferation and Fc epsilon RI expression. Allergy 61(9):1047–1053. https://doi.org/10.1111/j.1398-9995.2006.01139.x CrossRefPubMed

31.

Lee CC, Lin CL, Leu SJ, Lee YL (2018) Overexpression of notch ligand delta-like-1 by dendritic cells enhances their immunoregulatory capacity and exerts antiallergic effects on Th2-mediated allergic asthma in mice. Clin Immunol 187:58–67. https://doi.org/10.1016/j.clim.2017.10.005 CrossRefPubMed

32.

Shamji MH, Durham SR (2017) Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol 140(6):1485–1498. https://doi.org/10.1016/j.jaci.2017.10.010 CrossRefPubMed

33.

Garcia-Garcia ML, Calvo C, Ruiz S, Pozo F, Del Pozo V, Remedios L, Exposito N, Tellez A, Casas I (2017) Role of viral coinfections in asthma development. PLoS One 12(12):e0189083. https://doi.org/10.1371/journal.pone.0189083 CrossRefPubMedPubMedCentral

34.

Bradding P, Arthur G (2016) Mast cells in asthma--state of the art. Clin Expe Allergy 46(2):194–263. https://doi.org/10.1111/cea.12675 CrossRef

35.

Brightling CE, Kaur D, Berger P, Morgan AJ, Wardlaw AJ, Bradding P (2005) Differential expression of CCR3 and CXCR3 by human lung and bone marrow-derived mast cells: implications for tissue mast cell migration. J Leukoc Biol 77(5):759–766. https://doi.org/10.1189/jlb.0904511 CrossRefPubMed

36.

Kelsen SG, Aksoy MO, Yang Y, Shahabuddin S, Litvin J, Safadi F, Rogers TJ (2004) The chemokine receptor CXCR3 and its splice variant are expressed in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 287(3):L584–L591. https://doi.org/10.1152/ajplung.00453.2003 CrossRefPubMed

37.

Weller CL, Collington SJ, Hartnell A, Conroy DM, Kaise T, Barker JE, Wilson MS, Taylor GW, Jose PJ, Williams TJ (2007) Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 receptor 3. Proc Natl Acad Sci U S A 104(28):11712–11717. https://doi.org/10.1073/pnas.0701700104 CrossRefPubMedPubMedCentral

38.

Weller CL, Collington SJ, Brown JK, Miller HR, Al-Kashi A, Clark P, Jose PJ, Hartnell A, Williams TJ (2005) Leukotriene B4, an activation product of mast cells, is a chemoattractant for their progenitors. J Exp Med 201(12):1961–1971. https://doi.org/10.1084/jem.20042407 CrossRefPubMedPubMedCentral

39.

Girodet PO, Ozier A, Trian T, Begueret H, Ousova O, Vernejoux JM, Chanez P, Marthan R, Berger P, Tunon de Lara JM (2010) Mast cell adhesion to bronchial smooth muscle in asthma specifically depends on CD51 and CD44 variant 6. Allergy 65(8):1004–1012. https://doi.org/10.1111/j.1398-9995.2009.02308.x CrossRefPubMed

40.

Zanini A, Chetta A, Saetta M, Baraldo S, D'Ippolito R, Castagnaro A, Neri M, Olivieri D (2007) Chymase-positive mast cells play a role in the vascular component of airway remodeling in asthma. J Allergy Clin Immunol 120(2):329–333. https://doi.org/10.1016/j.jaci.2007.04.021 CrossRefPubMed

41.

Lefrancais E, Duval A, Mirey E, Roga S, Espinosa E, Cayrol C, Girard JP (2014) Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc Natl Acad Sci U S A 111(43):15502–15507. https://doi.org/10.1073/pnas.1410700111 CrossRefPubMedPubMedCentral

42.

Modena BD, Dazy K, White AA (2016) Emerging concepts: mast cell involvement in allergic diseases. Transl Res 174:98–121. https://doi.org/10.1016/j.trsl.2016.02.011 CrossRefPubMed

43.

Gauthier M, Chakraborty K, Oriss TB, Raundhal M, Das S, Chen J, Huff R, Sinha A, Fajt M, Ray P, Wenzel SE, Ray A (2017) Severe asthma in humans and mouse model suggests a CXCL10 signature underlies corticosteroid-resistant Th1 bias. JCI Insight 2(13). https://doi.org/10.1172/jci.insight.94580

44.

Scarpelli MP, Keller S, Tran L, Palmiere C (2016) Postmortem serum levels of IgE and mast cell tryptase in fatal asthma. Forensic Sci Int 269:113–118. https://doi.org/10.1016/j.forsciint.2016.11.001 CrossRefPubMed

45.

Lewis RJ, Chachi L, Newby C, Amrani Y, Bradding P (2016) Bidirectional counter regulation of human lung mast cell and airway smooth muscle beta2 adrenoceptors. J Immunol 196(1):55–63. https://doi.org/10.4049/jimmunol.1402232 CrossRefPubMed

46.

Parameswaran K, Radford K, Fanat A, Stephen J, Bonnans C, Levy BD, Janssen LJ, Cox PG (2007) Modulation of human airway smooth muscle migration by lipid mediators and Th-2 cytokines. Am J Respir Cell Mol Biol 37(2):240–247. https://doi.org/10.1165/rcmb.2006-0172OC CrossRefPubMed

47.

Singh D, Ravi A, Southworth T (2017) CRTH2 antagonists in asthma: current perspectives. Clin Pharmacol 9:165–173. https://doi.org/10.2147/cpaa.s119295 CrossRefPubMedPubMedCentral

48.

Arthur G, Bradding P (2016) New developments in mast cell biology: clinical implications. Chest 150(3):680–693. https://doi.org/10.1016/j.chest.2016.06.009 CrossRefPubMed

49.

Diamant Z, Mantzouranis E, Bjermer L (2009) Montelukast in the treatment of asthma and beyond. Expert Rev Clin Immunol 5(6):639–658. https://doi.org/10.1586/eci.09.62 CrossRefPubMed

50.

Lazarinis N, Bood J, Gomez C, Kolmert J, Lantz AS, Gyllfors P, Davis A, Wheelock CE, Dahlen SE, Dahlen B (2018) Leukotriene E4 induces airflow obstruction and mast cell activation via the CysLT1 receptor. J Allergy Clin Immunol 142:1080–1089. https://doi.org/10.1016/j.jaci.2018.02.024 CrossRefPubMed

51.

Kasperska-Zajac A, Brzoza Z, Rogala B (2008) Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy. Recent Patents Inflamm Allergy Drug Discov 2(1):72–76CrossRef

52.

KleinJan A (2016) Airway inflammation in asthma: key players beyond the Th2 pathway. Curr Opin Pulm Med 22(1):46–52. https://doi.org/10.1097/mcp.0000000000000224 CrossRefPubMed

53.

Carter RJ, Bradding P (2011) The role of mast cells in the structural alterations of the airways as a potential mechanism in the pathogenesis of severe asthma. Curr Pharm Des 17(7):685–698CrossRef

54.

Agrawal S, Townley RG (2014) Role of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthma. Expert Opin Biol Ther 14(2):165–181. https://doi.org/10.1517/14712598.2014.859673 CrossRefPubMed

55.

Hodsman P, Ashman C, Cahn A, De Boever E, Locantore N, Serone A, Pouliquen I (2013) A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics. Br J Clin Pharmacol 75(1):118–128. https://doi.org/10.1111/j.1365-2125.2012.04334.x CrossRefPubMed

56.

Reuter S, Stassen M, Taube C (2010) Mast cells in allergic asthma and beyond. Yonsei Med J 51(6):797–807. https://doi.org/10.3349/ymj.2010.51.6.797 CrossRefPubMedPubMedCentral

57.

Virk H, Arthur G, Bradding P (2016) Mast cells and their activation in lung disease. Transl Res 174:60–76. https://doi.org/10.1016/j.trsl.2016.01.005 CrossRefPubMed

58.

Nakae S, Morita H, Ohno T, Arae K, Matsumoto K, Saito H (2013) Role of interleukin-33 in innate-type immune cells in allergy. Allergol Int 62(1):13–20. https://doi.org/10.2332/allergolint.13-RAI-0538 CrossRefPubMed

59.

Keglowich LF, Borger P (2015) The three A’s in asthma - airway smooth muscle, airway remodeling & angiogenesis. Open Respir Med J 9:70–80. https://doi.org/10.2174/1874306401509010070 CrossRefPubMedPubMedCentral

60.

Naveed SU, Clements D, Jackson DJ, Philp C, Billington CK, Soomro I, Reynolds C, Harrison TW, Johnston SL, Shaw DE, Johnson SR (2017) Matrix metalloproteinase-1 activation contributes to airway smooth muscle growth and asthma severity. Am J Respir Crit Care Med 195(8):1000–1009. https://doi.org/10.1164/rccm.201604-0822OC CrossRefPubMedPubMedCentral

61.

Thiriou D, Morianos I, Xanthou G, Samitas K (2017) Innate immunity as the orchestrator of allergic airway inflammation and resolution in asthma. Int Immunopharmacol 48:43–54. https://doi.org/10.1016/j.intimp.2017.04.027 CrossRefPubMed

62.

Lai H, Rogers DF (2010) New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways. J Aerosol Med Pulm Drug Deliv 23(4):219–231. https://doi.org/10.1089/jamp.2009.0802 CrossRefPubMed

63.

Alevy YG, Patel AC, Romero AG, Patel DA, Tucker J, Roswit WT, Miller CA, Heier RF, Byers DE, Brett TJ, Holtzman MJ (2012) IL-13-induced airway mucus production is attenuated by MAPK13 inhibition. J Clin Invest 122(12):4555–4568. https://doi.org/10.1172/jci64896 CrossRefPubMedPubMedCentral

64.

Tyner JW, Kim EY, Ide K, Pelletier MR, Roswit WT, Morton JD, Battaile JT, Patel AC, Patterson GA, Castro M, Spoor MS, You Y, Brody SL, Holtzman MJ (2006) Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. J Clin Invest 116(2):309–321. https://doi.org/10.1172/jci25167 CrossRefPubMedPubMedCentral

65.

Lezmi G, Galmiche-Rolland L, Rioux S, Jaubert F, Tillie-Leblond I, Scheinmann P, Gosset P, de Blic J (2016) Mast cells are associated with exacerbations and eosinophilia in children with severe asthma. Eur Respir J 48(5):1320–1328. https://doi.org/10.1183/13993003.00947-2016 CrossRefPubMed

66.

Bradding P, Walls AF, Holgate ST (2006) The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 117(6):1277–1284. https://doi.org/10.1016/j.jaci.2006.02.039 CrossRefPubMed

67.

Wang G, Baines KJ, Fu JJ, Wood LG, Simpson JL, McDonald VM, Cowan DC, Taylor DR, Cowan JO, Gibson PG (2016) Sputum mast cell subtypes relate to eosinophilia and corticosteroid response in asthma. Eur Respir J 47(4):1123–1133. https://doi.org/10.1183/13993003.01098-2015 CrossRefPubMed

68.

Alkhouri H, Hollins F, Moir LM, Brightling CE, Armour CL, Hughes JM (2011) Human lung mast cells modulate the functions of airway smooth muscle cells in asthma. Allergy 66(9):1231–1241. https://doi.org/10.1111/j.1398-9995.2011.02616.x CrossRefPubMed

69.

Manning BM, Meyer AF, Gruba SM, Haynes CL (2015) Single-cell analysis of mast cell degranulation induced by airway smooth muscle-secreted chemokines. Biochim Biophys Acta 1850(9):1862–1868. https://doi.org/10.1016/j.bbagen.2015.05.008 CrossRefPubMedPubMedCentral

70.

Safholm J, Manson ML, Bood J, Delin I, Orre AC, Bergman P, Al-Ameri M, Dahlen SE, Adner M (2015) Prostaglandin E2 inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor. J Allergy Clin Immunol 136(5):1232–1239.e1231. https://doi.org/10.1016/j.jaci.2015.04.002 CrossRefPubMed

71.

Kay LJ, Gilbert M, Pullen N, Skerratt S, Farrington J, Seward EP, Peachell PT (2013) Characterization of the EP receptor subtype that mediates the inhibitory effects of prostaglandin E2 on IgE-dependent secretion from human lung mast cells. Clin Exp Allergy 43(7):741–751. https://doi.org/10.1111/cea.12142 CrossRefPubMed

72.

Aubier M, Thabut G, Hamidi F, Guillou N, Brard J, Dombret MC, Borensztajn K, Aitilalne B, Poirier I, Roland-Nicaise P, Taille C, Pretolani M (2016) Airway smooth muscle enlargement is associated with protease-activated receptor 2/ligand overexpression in patients with difficult-to-control severe asthma. J Allergy Clin Immunol 138(3):729–739.e711. https://doi.org/10.1016/j.jaci.2015.12.1332 CrossRefPubMed

73.

Allard B, Bara I, Gilbert G, Carvalho G, Trian T, Ozier A, Gillibert-Duplantier J, Ousova O, Maurat E, Thumerel M, Quignard JF, Girodet PO, Marthan R, Berger P (2014) Protease activated receptor-2 expression and function in asthmatic bronchial smooth muscle. PLoS One 9(2):e86945. https://doi.org/10.1371/journal.pone.0086945 CrossRefPubMedPubMedCentral

74.

Hirst SJ (2003) Regulation of airway smooth muscle cell immunomodulatory function: role in asthma. Respir Physiol Neurobiol 137(2–3):309–326CrossRef

75.

Rogers NK, Clements D, Dongre A, Harrison TW, Shaw D, Johnson SR (2014) Extra-cellular matrix proteins induce matrix metalloproteinase-1 (MMP-1) activity and increase airway smooth muscle contraction in asthma. PLoS One 9(2):e90565. https://doi.org/10.1371/journal.pone.0090565 CrossRefPubMedPubMedCentral

76.

Bergeron C, Tulic MK, Hamid Q (2010) Airway remodelling in asthma: from benchside to clinical practice. Can Respir J 17(4):e85–e93CrossRef

77.

Halwani R, Al-Muhsen S, Al-Jahdali H, Hamid Q (2011) Role of transforming growth factor-beta in airway remodeling in asthma. Am J Respir Cell Mol Biol 44(2):127–133. https://doi.org/10.1165/rcmb.2010-0027TR CrossRefPubMed

78.

Margulis A, Nocka KH, Brennan AM, Deng B, Fleming M, Goldman SJ, Kasaian MT (2009) Mast cell-dependent contraction of human airway smooth muscle cell-containing collagen gels: influence of cytokines, matrix metalloproteases, and serine proteases. J Immunol 183(3):1739–1750. https://doi.org/10.4049/jimmunol.0803951 CrossRefPubMed

79.

Davies AM, Allan EG, Keeble AH, Delgado J, Cossins BP, Mitropoulou AN, Pang MOY, Ceska T, Beavil AJ, Craggs G, Westwood M, Henry AJ, McDonnell JM, Sutton BJ (2017) Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab. J Biol Chem 292(24):9975–9987. https://doi.org/10.1074/jbc.M117.776476 CrossRefPubMedPubMedCentral

80.

Mizuma H, Tanaka A, Uchida Y, Fujiwara A, Manabe R, Furukawa H, Kuwahara N, Fukuda Y, Kimura T, Jinno M, Ohta S, Yamamoto M, Matsukura S, Adachi M, Sagara H (2015) Influence of omalizumab on allergen-specific IgE in patients with adult asthma. Int Arch Allergy Immunol 168(3):165–172. https://doi.org/10.1159/000442668 CrossRefPubMed

81.

Cohen ES, Dobson CL, Kack H, Wang B, Sims DA, Lloyd CO, England E, Rees DG, Guo H, Karagiannis SN, O'Brien S, Persdotter S, Ekdahl H, Butler R, Keyes F, Oakley S, Carlsson M, Briend E, Wilkinson T, Anderson IK, Monk PD, von Wachenfeldt K, Eriksson PO, Gould HJ, Vaughan TJ, May RD (2014) A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs 6(3):756–764. https://doi.org/10.4161/mabs.28394 CrossRefPubMed

82.

Caslin HL, Kiwanuka KN, Haque TT, Taruselli MT, MacKnight HP, Paranjape A, Ryan JJ (2018) Controlling mast cell activation and homeostasis: work influenced by Bill Paul that continues today. Front Immunol 9:868. https://doi.org/10.3389/fimmu.2018.00868 CrossRefPubMedPubMedCentral

83.

Peters SP, Busse WW (2017) New and anticipated therapies for severe asthma. J Allergy Clin Immunol Pract 5s(5):S15–s24. https://doi.org/10.1016/j.jaip.2017.07.008 CrossRef

84.

Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, Vandenberghe I, Pauwels K (2017) Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma. Nat Commun 8:14937. https://doi.org/10.1038/ncomms14937 CrossRefPubMedPubMedCentral

85.

Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Casteran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O (2009) Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 4(9):e7258. https://doi.org/10.1371/journal.pone.0007258 CrossRefPubMedPubMedCentral

86.

Koziol-White CJ, Jia Y, Baltus GA, Cooper PR, Zaller DM, Crackower MA, Sirkowski EE, Smock S, Northrup AB, Himes BE, Alves SE, Panettieri RA Jr (2016) Inhibition of spleen tyrosine kinase attenuates IgE-mediated airway contraction and mediator release in human precision cut lung slices. Br J Pharmacol 173(21):3080–3087. https://doi.org/10.1111/bph.13550 CrossRefPubMedPubMedCentral

87.

Moy LY, Jia Y, Caniga M, Lieber G, Gil M, Fernandez X, Sirkowski E, Miller R, Alexander JP, Lee HH, Shin JD, Ellis JM, Chen H, Wilhelm A, Yu H, Vincent S, Chapman RW, Kelly N, Hickey E, Abraham WM, Northrup A, Miller T, Houshyar H, Crackower MA (2013) Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction. Am J Respir Cell Mol Biol 49(6):1085–1092. https://doi.org/10.1165/rcmb.2013-0200OC CrossRefPubMed

88.

Ramis I, Otal R, Carreno C, Domenech A, Eichhorn P, Orellana A, Maldonado M, De Alba J, Prats N, Fernandez JC, Vidal B, Miralpeix M (2015) A novel inhaled Syk inhibitor blocks mast cell degranulation and early asthmatic response. Pharmacol Res 99:116–124. https://doi.org/10.1016/j.phrs.2015.05.011 CrossRefPubMed

89.

Hall IP, Fowler AV, Gupta A, Tetzlaff K, Nivens MC, Sarno M, Finnigan HA, Bateman ED, Rand Sutherland E (2015) Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. Pulm Pharmacol Ther 32:37–44. https://doi.org/10.1016/j.pupt.2015.03.003 CrossRefPubMed

90.

Cahill KN, Katz HR, Cui J, Lai J, Kazani S, Crosby-Thompson A, Garofalo D, Castro M, Jarjour N, DiMango E, Erzurum S, Trevor JL, Shenoy K, Chinchilli VM, Wechsler ME, Laidlaw TM, Boyce JA, Israel E (2017) KIT inhibition by imatinib in patients with severe refractory asthma. N Engl J Med 376(20):1911–1920. https://doi.org/10.1056/NEJMoa1613125 CrossRefPubMedPubMedCentral

91.

Rhee CK, Kim JW, Park CK, Kim JS, Kang JY, Kim SJ, Kim SC, Kwon SS, Kim YK, Park SH, Lee SY (2011) Effect of imatinib on airway smooth muscle thickening in a murine model of chronic asthma. Int Arch Allergy Immunol 155(3):243–251. https://doi.org/10.1159/000321261 CrossRefPubMed

92.

Patel KR, Aven L, Shao F, Krishnamoorthy N, Duvall MG, Levy BD, Ai X (2016) Mast cell-derived neurotrophin 4 mediates allergen-induced airway hyperinnervation in early life. Mucosal Immunol 9(6):1466–1476. https://doi.org/10.1038/mi.2016.11 CrossRefPubMedPubMedCentral

93.

Wang Q, Chen D, Xie H, Lin X, Wang X, Yao Q, Zheng X, Xu C, Chen L, He S, Zhang H (2016) Altered expression of IFN-lambda2 in allergic airway disorders and identification of its cell origins. Mediat Inflamm 2016:5759496. https://doi.org/10.1155/2016/5759496 CrossRef

94.

Conti P, Ronconi G, Caraffa A, Lessiani G, Duraisamy K (2017) IL-37 a new IL-1 family member emerges as a key suppressor of asthma mediated by mast cells. Immunol Investig 46(3):239–250. https://doi.org/10.1080/08820139.2016.1250220 CrossRef

95.

Bezemer GF, Sagar S, van Bergenhenegouwen J, Georgiou NA, Garssen J, Kraneveld AD, Folkerts G (2012) Dual role of Toll-like receptors in asthma and chronic obstructive pulmonary disease. Pharmacol Rev 64(2):337–358. https://doi.org/10.1124/pr.111.004622 CrossRefPubMed

96.

Zhang H, Wang J, Wang L, Xie H, Chen L, He S (2018) Role of IL-18 in atopic asthma is determined by balance of IL-18/IL-18BP/IL-18R. J Cell Mol Med 22(1):354–373. https://doi.org/10.1111/jcmm.13323 CrossRefPubMed

97.

Wang J, Zhang H, Zheng W, Xie H, Yan H, Lin X, He S (2016) Correlation of IL-18 with tryptase in atopic asthma and induction of mast cell accumulation by IL-18. Mediat Inflamm 2016:4743176–4743114. https://doi.org/10.1155/2016/4743176 CrossRef

98.

Paivandy A, Sandelin M, Igelstrom H, Landelius P, Janson C, Melo FR, Pejler G (2017) Induction of human lung mast cell apoptosis by granule permeabilization: a novel approach for targeting mast cells. Front Immunol 8:1645. https://doi.org/10.3389/fimmu.2017.01645 CrossRefPubMedPubMedCentral

99.

Wareham KJ, Seward EP (2016) P2X7 receptors induce degranulation in human mast cells. Purinergic Signal 12(2):235–246. https://doi.org/10.1007/s11302-016-9497-4 CrossRefPubMedPubMedCentral

100.

Lee AJ, Ro M, Cho KJ, Kim JH (2017) Lipopolysaccharide/TLR4 stimulates IL-13 production through a MyD88-BLT2-linked cascade in mast cells, potentially contributing to the allergic response. J Immunol 199(2):409–417. https://doi.org/10.4049/jimmunol.1602062 CrossRefPubMed

101.

Suurmond J, Habets KLL, Tatum Z, Schonkeren JJ, Hoen PAC, Huizinga TWJ, Laros JFJ, Toes REM, Kurreeman F (2016) Repeated FcepsilonRI triggering reveals modified mast cell function related to chronic allergic responses in tissue. J Allergy Clin Immunol 138(3):869–880. https://doi.org/10.1016/j.jaci.2016.01.017 CrossRefPubMed

102.

Yoshioka M, Fukuishi N, Iriguchi S, Ohsaki K, Yamanobe H, Inukai A, Kurihara D, Imajo N, Yasui Y, Matsui N, Tsujita T, Ishii A, Seya T, Takahama M, Akagi M (2007) Lipoteichoic acid downregulates FcepsilonRI expression on human mast cells through Toll-like receptor 2. J Allergy Clin Immunol 120(2):452–461. https://doi.org/10.1016/j.jaci.2007.03.027 CrossRefPubMed

103.

Suzuki Y, Wakahara K (2017) Airway basophils are increased and activated in eosinophilic asthma. Allergy 72(10):1532–1539. https://doi.org/10.1111/all.13197 CrossRefPubMed

104.

Sancho-Chust JN, Chiner E, Camarasa A, Llombart M (2009) Recent-onset bronchial asthma as a manifestation of systemic mastocytosis. J Investig Allergol Clin Immunol 19(6):513–515PubMed

Title: Mast Cell-Mediated Orchestration of the Immune Responses in Human Allergic Asthma: Current Insights
Authors: Daniel Elieh Ali Komi
Leif Bjermer
Publication date: 01-04-2019
Publisher: Springer US
Published in: Clinical Reviews in Allergy & Immunology / Issue 2/2019
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-018-8720-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease

Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema

CD26 and Asthma: a Comprehensive Review

Inner-City Asthma in Children

Allergy and Asthma Care in the Mobile Phone Era

Fractional Exhaled Nitric Oxide for the Diagnosis of Childhood Asthma: a Systematic Review and Meta-analysis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage